In neuroblastoma, lorlatinib has demonstrated promising results as a single agent in various pre-clinical models, being able to overcome crizotinib resistance and showing dramatic inhibition of tumor growth of neuroblastoma xenografts or MYCN and ALKF1174L driven tumors in a transgenic mouse model [42, 43]. This evidence concerns the gene MYCN and neoplasm.